Form 4: Esperion Therapeutics Director Nicole Vitullo Granted 88,000 Stock Options
Insider Transaction Report
Esperion Therapeutics, Inc. Director Nicole Vitullo was granted 88,000 stock options with an exercise price of $0.87, as disclosed in a recent SEC Form 4 filing.
Summary
- Nicole Vitullo, a Director of Esperion Therapeutics, Inc. (ESPR), was granted 88,000 stock options.
- The transaction date for this grant was May 29, 2025.
- Each stock option has an exercise price of $0.87.
- The options are exercisable as of May 29, 2025, and have an expiration date of May 29, 2035.
- The awards will vest in full on the earlier of May 29, 2026, or the Issuer's next annual meeting of stockholders following May 29, 2025.
- Following this transaction, Nicole Vitullo beneficially owns 88,000 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The sentiment is mildly positive as it represents a standard compensation grant to a director, aligning their interests with shareholders, without indicating any immediate negative operational or financial news.
Positives
- The grant of stock options to Director Nicole Vitullo aligns her interests with those of shareholders, as the value of the options increases with the company's stock price.
- The exercise price of $0.87 per share is relatively low, potentially offering significant upside if the company's stock performs well.
Negatives
- The issuance of new stock options could lead to potential dilution for existing shareholders if the options are exercised in the future.
Future Outlook
The document indicates future vesting events for the granted stock options, with full vesting occurring on the earlier of May 29, 2026, or the Issuer's next annual meeting of stockholders following May 29, 2025.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity, specifically a compensation grant to a director, which is a common practice in the biotechnology and pharmaceutical industry to incentivize and retain key personnel.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization for SEC Filings | Nicole Vitullo granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker to execute and file SEC forms (Form ID, 3, 4, 5, Schedule 13D) on her behalf as an officer and/or director of Esperion Therapeutics, Inc. | 05/24/2022 | Streamlines the process for insider reporting compliance, ensuring timely and accurate filings with the SEC. |
Related Party Transactions
- The grant of 88,000 stock options to Nicole Vitullo, a Director of Esperion Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.
Stakeholder Impact
- Shareholders: Potential future dilution if options are exercised, but also increased alignment of director's interests with shareholder value creation.
- Director (Nicole Vitullo): Receives equity-based compensation, providing a direct financial incentive tied to the company's performance.
Next Steps
- The stock options will vest in full on the earlier of May 29, 2026, or the Issuer's next annual meeting of stockholders following May 29, 2025.
Key Dates
| Date | Description |
|---|---|
| 05/24/2022 | Date of Limited Power of Attorney granted by Nicole Vitullo to Sheldon Koenig and Benjamin Looker for SEC filings. |
| 05/29/2025 | Transaction date for the stock option grant to Nicole Vitullo, also the date the options become exercisable. |
| 06/02/2025 | Date the Form 4 filing was signed by power of attorney. |
| 05/29/2026 | Earliest date for full vesting of the stock option awards. |
| 05/29/2035 | Expiration date of the granted stock options. |
Keywords
Esperion Therapeutics, ESPR, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.